Does SummaCare Cover Prolia (Denosumab)?

What Is Prolia and Why Does Coverage Complexity Exist?

Prolia is the brand name for denosumab, a fully human monoclonal antibody that inhibits RANK-L (receptor activator of nuclear factor kappa-B ligand), blocking osteoclast formation and reducing bone resorption. The FDA approved it in June 2010 for postmenopausal women with osteoporosis at high risk of fracture, and subsequently for men with osteoporosis, glucocorticoid-induced bone loss, and bone loss from hormone-ablation therapy in certain cancers. 1

Why Insurance Complexity Arises for an Injectable Drug

Most oral osteoporosis drugs (alendronate, risedronate) are dispensed at retail pharmacies and covered under Part D or a commercial pharmacy benefit. Prolia is different. It is a biologic injectable that must be administered by a healthcare provider, so it is billed as a medical service under HCPCS code J0897. That single structural difference means the drug travels through the medical benefit, which has its own utilization management rules separate from formulary tiers.

SummaCare, a health plan headquartered in Akron, Ohio, that serves members across northeast Ohio and beyond, requires prior authorization for J0897 claims. The authorization criteria align with published clinical guidelines but add plan-specific step-therapy requirements.

Clinical Evidence Driving the Coverage Standard

The FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every 6 months over 36 months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% compared with placebo in postmenopausal women with a lumbar spine or total hip T-score between -2.5 and -4.0. 2 That evidence base is precisely what insurers use to define the eligible population, which is why T-score thresholds appear so prominently in prior authorization forms.

The American Society for Bone and Mineral Research and the Endocrine Society both recognize denosumab as a first-line option for patients who cannot tolerate bisphosphonates or have renal impairment (estimated GFR <35 mL/min/1.73 m²). 3

How SummaCare Structures Its Medical Benefit for Injectables

SummaCare offers several plan lines, including employer-sponsored commercial plans, Medicare Advantage (SummaCare Medicare), and individual/family plans through the Ohio marketplace. Coverage rules for Prolia differ modestly across these lines.

Commercial (Employer-Sponsored) Plans

Under commercial plans, Prolia falls in the specialty drug tier of the medical benefit. Prior authorization is required, and the plan's preferred sequence generally follows this path:

1. Documented DXA scan T-score of -2.5 or below at the lumbar spine, femoral neck, or total hip.
2. A 3- to 6-month documented trial of an oral bisphosphonate (typically alendronate 70 mg weekly or risedronate 35 mg weekly) unless contraindicated.
3. A signed order from the treating physician specifying the diagnosis code (M81.0 for postmenopausal osteoporosis, or the relevant ICD-10 code for secondary osteoporosis).

Contraindications to bisphosphonates that SummaCare recognizes as step-therapy bypasses include: esophageal disorders preventing upright positioning, severe renal impairment, hypocalcemia, and documented intolerance such as severe GI toxicity.

Medicare Advantage Plans

SummaCare's Medicare Advantage products follow CMS coverage policy for denosumab. Under Medicare Part B, Prolia is covered when the drug is furnished incident to a physician's service and the beneficiary meets clinical criteria consistent with the FDA label. 4 The treating provider must document osteoporosis (T-score -2.5 or lower) or osteopenia with a prior fragility fracture.

Because CMS sets the framework, Medicare Advantage plans including SummaCare Medicare cannot impose more restrictive criteria than traditional Medicare for services that Medicare covers. Plans may require prior authorization as a procedural step even when clinical criteria are met.

Marketplace (ACA) Plans

Marketplace plans sold by SummaCare must comply with ACA essential health benefit rules. Osteoporosis treatment is covered under the preventive care and chronic disease management categories. Step-therapy and prior authorization rules still apply, but the Affordable Care Act limits how far insurers can delay medically necessary care.

Prior Authorization: Step-by-Step for Prolia

Getting prior authorization approved the first time saves weeks of delay. Here is a practical sequence your prescriber's office should follow.

Documents to Gather Before Submitting

• DXA scan report with T-scores for lumbar spine (L1-L4) and left femoral neck, performed within the past 24 months.
• FRAX score calculation if the T-score falls in the osteopenia range (-1.0 to -2.4) but a prior fragility fracture has occurred. The FRAX tool, maintained by the University of Sheffield, calculates 10-year fracture probability and is widely accepted by payers. 5
• Documentation of prior bisphosphonate therapy: drug name, dose, duration, and reason for discontinuation or contraindication.
• Serum calcium and vitamin D levels (to screen for hypocalcemia before starting denosumab). 6
• Prescriber's letter of medical necessity on letterhead, citing the diagnosis code and clinical rationale.

Submitting the PA Request

SummaCare accepts prior authorization requests via its provider portal, fax, or phone. Standard review turnaround is up to 3 business days. Urgent reviews, where a delay would seriously jeopardize health, must be completed within 72 hours under Ohio insurance law and federal managed care regulations. 7

Common Reasons for First-Pass Denial

• Missing DXA report or a DXA older than 24 months.
• No documentation of bisphosphonate trial or contraindication.
• Diagnosis code mismatch (for example, submitting M85.80 instead of M81.0).
• Provider NPI not credentialed with SummaCare for the service location.

What Prolia Costs Under SummaCare

Out-of-pocket cost depends on which SummaCare plan you carry and whether your deductible has been met.

Medical Benefit Cost-Sharing

Because Prolia is billed as a medical claim (J0897), cost-sharing is applied against your medical deductible and out-of-pocket maximum, not your pharmacy deductible. The drug's average sales price (ASP) per dose is roughly $1,350 to $1,550 for the 60 mg/mL prefilled syringe, though this fluctuates with CMS quarterly ASP updates. 8

Under a typical SummaCare commercial plan with a $2,000 individual deductible and 20% coinsurance after deductible, a patient who has met their deductible pays roughly $270 to $310 per injection, or $540 to $620 per year for both doses.

Manufacturer Assistance: Amgen's Prolia Support Program

Amgen runs a co-pay assistance program for commercially insured patients. Eligible patients may pay as little as $0 per dose, with the program covering up to a defined annual cap. Patients on Medicare or Medicaid are not eligible for co-pay cards, but the Amgen Safety Net Foundation offers free medication to uninsured or underinsured patients who meet income thresholds. 9

The table below summarizes approximate annual out-of-pocket exposure by plan type before any manufacturer assistance is applied.

| Plan Type | Typical Annual OOP (2 doses) | Notes | |---|---|---| | Commercial, deductible met | $540 - $620 | 20% coinsurance on ASP | | Commercial, deductible not met | $2,700 - $3,100 | Full ASP until deductible met | | Medicare Advantage (20% Part B coinsurance) | $270 - $310 | After Part B deductible of $240 (2024) | | Marketplace silver plan | Varies by CSR tier | Cost-sharing reductions may apply |

Clinical Context: Who Qualifies for Prolia?

Understanding clinical eligibility helps you anticipate whether SummaCare will approve the request without a fight.

Postmenopausal Osteoporosis

The primary FDA-approved indication, and the most common reason Prolia is prescribed, is postmenopausal osteoporosis in women at high fracture risk. "High fracture risk" is operationally defined by the Endocrine Society as a T-score of -2.5 or below, or a prior hip or vertebral fracture. 10

National Osteoporosis Foundation data estimate that roughly 10 million Americans have osteoporosis and another 44 million have low bone density, placing more than half of adults over age 50 at fracture risk. 11 That scale makes osteoporosis treatment one of the higher-volume prior authorization categories for plans like SummaCare.

Glucocorticoid-Induced Osteoporosis

Patients on long-term glucocorticoid therapy (prednisone 5 mg/day or more for 3 months or longer) face accelerated bone loss. The American College of Rheumatology 2022 guidelines recommend denosumab as a high-risk treatment option in this population when bisphosphonates are not tolerated or are contraindicated. 12 SummaCare's PA criteria for this indication typically require documentation of the steroid dose, duration, and either a T-score below -2.5 or a fragility fracture.

Oncology-Related Bone Loss

Men with nonmetastatic prostate cancer on androgen-deprivation therapy (ADT) and women with breast cancer on aromatase inhibitors experience rapid bone loss. The FDA label covers these indications. Dosing and coverage pathways may differ slightly from the osteoporosis indication, and oncology teams usually coordinate PA with the plan's oncology case managers.

Renal Impairment

Oral bisphosphonates are contraindicated when the estimated GFR is <35 mL/min/1.73 m². Denosumab is not renally cleared and is considered safe in this population, though hypocalcemia risk rises in severe renal disease. 13 Documenting GFR below the bisphosphonate threshold is one of the cleanest step-therapy bypass arguments available to prescribers.

What Happens If SummaCare Denies Coverage?

A denial is not a final answer. Ohio law and federal regulations give you specific rights.

First-Level Internal Appeal

File a written appeal within 60 days of receiving the adverse determination letter. Attach all clinical documentation plus a letter from the treating physician explaining why Prolia is medically necessary and why alternatives are inappropriate. SummaCare must respond within 30 days for standard appeals and 72 hours for expedited appeals. 14

Second-Level Appeal and Independent Review

If the first-level appeal is denied, Ohio-insured members have the right to an external independent review through the Ohio Department of Insurance. The external reviewer is an independent organization with no financial relationship to SummaCare, and its decision is binding on the insurer for most plan types. Enrollment in a grandfathered plan may affect external review rights.

Peer-to-Peer Review

Before a formal appeal, ask for a peer-to-peer call between the treating physician and SummaCare's medical director. This step often resolves denials faster than the written appeal process. The clinical reviewer may approve coverage once they hear the specific patient history directly. Peer-to-peer requests are typically available within 2 business days of a denial.

Switching Agents if Coverage Fails

If coverage for Prolia cannot be secured after appeals, alternative agents with established evidence include:

• Zoledronic acid (Reclast) 5 mg IV once yearly. The HORIZON Key Fracture Trial (N=7,765) showed a 70% reduction in vertebral fracture risk over 3 years versus placebo. 15 This is also a medical-benefit drug (J3488), but it tends to have broader first-line coverage.
• Romosozumab (Evenity) 210 mg SC monthly for 12 months, for patients with very high fracture risk. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced vertebral fracture risk by 48% vs. Alendronate alone at 24 months. 16
• Teriparatide (Forteo) 20 mcg SC daily for up to 24 months, an anabolic agent for severe osteoporosis. 17

Discontinuing Prolia: A Coverage Detail Prescribers Must Communicate

One pharmacological fact that directly affects coverage decisions is the rebound effect after stopping denosumab. Multiple case series have documented rapid bone loss and vertebral fractures within 12 to 18 months of denosumab discontinuation, with fracture incidence rising to approximately 3 to 7 vertebral fractures per 100 patient-years in the off-treatment window. 18

The American Association of Clinical Endocrinology 2020 guideline states: "Patients who discontinue denosumab should receive sequential antiresorptive therapy, typically with a bisphosphonate, to preserve the gains in bone density." 19

This clinical reality means that if SummaCare denies a renewal prior authorization, the prescriber's appeal should include this rebound fracture risk data as part of the medical necessity argument. Stopping Prolia without a transition plan is not a clinically neutral act.

Key Differences Between Prolia and Xgeva: Why It Matters for Coverage

Denosumab is marketed under two brand names: Prolia (60 mg every 6 months) and Xgeva (120 mg every 4 weeks). They are the same molecule at different doses and FDA-approved for different indications.

Xgeva is approved for prevention of skeletal-related events in patients with bone metastases from solid tumors and for giant cell tumor of bone. 20 It is billed under a different HCPCS code and covered under oncology benefit management rules, not the standard osteoporosis prior authorization pathway.

Prescribing Prolia when Xgeva is indicated, or vice versa, generates an automatic denial based on diagnosis-code mismatch. Verify the brand name and indication before submitting the PA.

Monitoring Requirements That Support Continued Coverage

SummaCare's continued-coverage criteria for Prolia renewal at 6 months typically include documented compliance and a plan for ongoing monitoring. The FDA label and clinical guidelines recommend:

• Serum calcium checked before each dose to rule out hypocalcemia. 21
• Vitamin D repletion to at least 30 ng/mL before each injection.
• Dental examination before initiating therapy and periodically thereafter (osteonecrosis of the jaw risk, though lower with Prolia than with Xgeva doses). 22
• DXA scan every 1 to 2 years to document treatment response.

Submitting these monitoring records with the renewal PA request signals to SummaCare's utilization reviewers that the prescribing team is following evidence-based protocols, which strengthens renewal approval rates.

Practical Tips for Patients and Prescribers

A few straightforward steps reduce denial rates and cost burden.

For Patients

Get a DXA scan done at a SummaCare-credentialed facility so the imaging report is directly linked to your member record. Ask your prescriber's office to verify your benefits before the appointment, not after the injection is given. An injection administered before authorization is approved may result in a claim denial that is very difficult to overturn retroactively.

Enroll in Amgen's Prolia support program at the same time the prior authorization is submitted. Processing takes a few days, and having the co-pay card ready before the first injection prevents out-of-pocket surprise. 23

For Prescribers

Use the SummaCare provider portal to check real-time authorization status. Fax-based PA submissions add 24 to 48 hours to turnaround time. When submitting the letter of medical necessity, include the specific T-score value, the FRAX 10-year hip fracture probability if applicable, and a direct sentence addressing step therapy (for example, "Patient failed a 6-month trial of alendronate 70 mg weekly due to erosive esophagitis documented on EGD dated [date]").

Ohio Senate Bill 265 (effective 2022) requires commercial health plans to implement a continuity-of-care provision for step therapy: patients already stable on a non-preferred drug cannot be forced to switch unless there is a documented clinical reason. If your patient has been on Prolia for more than 12 months and is stable, cite this provision in any step-therapy override request. 24